Benoit You, Medical Oncologist at Hospices Civils de Lyon, shared on LinkedIn:
“Now online in JAMA Oncology:
Title: Rethinking Treatment Intensification in Poorly Chemosensitive Ovarian Cancer .
Authors: Benoit You, Andrew Clamp, Kathleen N. Moore, Stephanie Lheureux, Ilan Bruchim, Pauline Corbaux, Hyun-Woong Cho, Maria del Pilar Estevez-Diz, Gilles Freyer, Rosalind M. Glasspool, Antonio González-Martín, Charlie Gourley, Philipp Harter, Judith R. Kroep, Alexandra Leary, Myong Cheol Lim, Domenica Lorusso, Claudia Marchetti, Christian Marth, Bradley J. Monk, Robert D. Morgan, Asima Mukhopadhyay, Alexander B. Olawaiye, Gabriella Maria Parma, Marc-Edy Pierre, Ka Yu Tse, Nozomu Yanaihara, Isabelle Ray-Coquard
Despite PARPi and bevacizumab, outcomes remain poor in advanced HGSOC with poorly chemosensitive disease not amenable to complete cytoreduction:
- The 2 red flags population.
We propose a response-adapted first-line strategy: early identification of poor chemosensitivity during neoadjuvant chemotherapy, then selective intensification before maintenance.
This concept is now being tested prospectively in the phase 3 SALVOVAR and phase 1/2 RegeNovar trials .”
You can also read:
